37 results
8-K
EX-10.1
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union
424B5
xcvpf4 8vf5fncc9
1 Feb 24
Prospectus supplement for primary offering
4:49pm
8-K
EX-10.1
dto5t8lcws n81e
1 Feb 24
Entry into a Material Definitive Agreement
4:09pm
424B3
hu0p9fu1
4 Apr 23
Prospectus supplement
4:57pm
POS AM
6o7oro
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
8-K
EX-10.1
2wghg y5c
16 May 22
Entry into a Material Definitive Agreement
9:49pm